Skip to main content

Jim Cramer on Pfizer's Trillium Deal: Oncology Is Ripe for Speculation

Publish date:
Video Rating:
Video Duration:

Pfizer  (PFE) - Get Free Report said it will buy Trillium Therapeutics  (TRIL) - Get Free Report in a deal that values the immuno-oncology specialist at $2.26 billion. 

Reacting to the deal, in addition to news of the Food and Drug Administration's approval and Pfizer and BioNtech's  (BNTX) - Get Free Report COVID vaccine, Jim Cramer said oncology companies are ripe for speculation if investors recognize the risk. 

"Don't give up the ship on any oncology stock if they have trials," Cramer said. 

Catch Cramer's full take in the video above. 

Recap TheStreet Live: Everything Jim Cramer Is Watching 8/23/21

Hear what Jim Cramer is only telling members of his Action Alerts PLUS investing club in Monday's Daily Rundown. 

Related Videos